Compare BNBX & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNBX | ADIL |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5M | 6.4M |
| IPO Year | N/A | 2018 |
| Metric | BNBX | ADIL |
|---|---|---|
| Price | $1.62 | $0.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 267.8K | ★ 362.7K |
| Earning Date | 02-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,136,935.00 | N/A |
| Revenue This Year | $253.12 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.11 | N/A |
| 52 Week Low | $1.16 | $0.22 |
| 52 Week High | $183.75 | $1.30 |
| Indicator | BNBX | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 36.83 |
| Support Level | N/A | $0.22 |
| Resistance Level | N/A | $0.27 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 31.44 |
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.